<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Cancer Cell Int</journal-id>
    <journal-id journal-id-type="iso-abbrev">Cancer Cell Int</journal-id>
    <journal-title-group>
      <journal-title>Cancer Cell International</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1475-2867</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7236197</article-id>
    <article-id pub-id-type="publisher-id">1262</article-id>
    <article-id pub-id-type="doi">10.1186/s12935-020-01262-3</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Primary Research</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title><italic>OSskcm</italic>: an online survival analysis webserver for skin cutaneous melanoma based on 1085 transcriptomic profiles</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8219-466X</contrib-id>
        <name>
          <surname>Zhang</surname>
          <given-names>Lu</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Wang</surname>
          <given-names>Qiang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Lijie</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Xie</surname>
          <given-names>Longxiang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>An</surname>
          <given-names>Yang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Guosen</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhu</surname>
          <given-names>Wan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Yongqiang</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Zhihui</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Zhang</surname>
          <given-names>Xiaochen</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tang</surname>
          <given-names>Panpan</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Huo</surname>
          <given-names>Xiaozheng</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5190-1253</contrib-id>
        <name>
          <surname>Guo</surname>
          <given-names>Xiangqian</given-names>
        </name>
        <address>
          <email>xqguo@henu.edu.cn</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.256922.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9139 560X</institution-id><institution>Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, School of Software, School of Basic Medical Sciences, </institution><institution>Henan University, </institution></institution-wrap>Kaifeng, 475004 Henan China </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.256922.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9139 560X</institution-id><institution>Henan Provincial Engineering Centre for Tumor Molecular Medicine, </institution><institution>Henan University, </institution></institution-wrap>Kaifeng, 475004 Henan China </aff>
      <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.168010.e</institution-id><institution-id institution-id-type="ISNI">0000000419368956</institution-id><institution>Department of Anesthesia, </institution><institution>Stanford University, </institution></institution-wrap>Stanford, CA 94305 USA </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>5</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>5</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2020</year>
    </pub-date>
    <volume>20</volume>
    <elocation-id>176</elocation-id>
    <history>
      <date date-type="received">
        <day>27</day>
        <month>1</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>13</day>
        <month>5</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2020</copyright-statement>
      <license license-type="OpenAccess">
        <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Cutaneous melanoma is one of the most aggressive and lethal skin cancers. It is greatly important to identify prognostic biomarkers to guide the clinical management. However, it is technically challenging for untrained researchers to process high dimensional profiling data and identify potential prognostic genes in profiling datasets.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p id="Par2">In this study, we developed a webserver to analyze the prognostic values of genes in cutaneous melanoma using data from TCGA and GEO databases. The webserver is named Online consensus Survival webserver for Skin Cutaneous Melanoma (<italic>OSskcm</italic>) which includes 1085 clinical melanoma samples. The <italic>OSskcm</italic> is hosted in a windows tomcat server. Server-side scripts were developed in Java script. The database system is managed by a SQL Server, which integrates gene expression data and clinical data. The Kaplan–Meier (KM) survival curves, Hazard ratio (HR) and 95% confidence interval (95%CI) were calculated in a univariate Cox regression analysis.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p id="Par3">In <italic>OSskcm</italic>, by inputting official gene symbol and selecting proper options, users could obtain KM survival plot with log-rank <italic>P</italic> value and HR on the output web page. In addition, clinical characters including race, stage, gender, age and type of therapy could also be included in the prognosis analysis as confounding factors to constrain the analysis in a subgroup of melanoma patients.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p id="Par4">The <italic>OSskcm</italic> is highly valuable for biologists and clinicians to perform the assessment and validation of new or interested prognostic biomarkers for melanoma. <italic>OSskcm</italic> can be accessed online at: <ext-link ext-link-type="uri" xlink:href="http://bioinfo.henu.edu.cn/Melanoma/MelanomaList.jsp">http://bioinfo.henu.edu.cn/Melanoma/MelanomaList.jsp</ext-link>.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Cutaneous melanoma</kwd>
      <kwd>Survival</kwd>
      <kwd>Prognosis</kwd>
      <kwd>Biomarker</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id>
            <institution>National Natural Science Foundation of China</institution>
          </institution-wrap>
        </funding-source>
        <award-id>No.81602362</award-id>
        <principal-award-recipient>
          <name>
            <surname>Guo</surname>
            <given-names>Xiangqian</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Program for Innovative Talents of Science and Technology in Henan Province</institution>
        </funding-source>
        <award-id>No. 18HASTIT048</award-id>
        <principal-award-recipient>
          <name>
            <surname>Guo</surname>
            <given-names>Xiangqian</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Kaifeng Science and Technology Major Project</institution>
        </funding-source>
        <award-id>18ZD008</award-id>
        <principal-award-recipient>
          <name>
            <surname>Guo</surname>
            <given-names>Xiangqian</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Supporting grant of Bioinformatics Center of Henan University</institution>
        </funding-source>
        <award-id>No.2018YLJC01</award-id>
        <award-id>No.2019YLXKJC01</award-id>
        <principal-award-recipient>
          <name>
            <surname>Guo</surname>
            <given-names>Xiangqian</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>Student Innovation and Entrepreneurship Training Program of Henan University</institution>
        </funding-source>
        <award-id>No. 2019101905</award-id>
        <principal-award-recipient>
          <name>
            <surname>Zhang</surname>
            <given-names>Lu</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2020</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par17">Cutaneous melanoma (CM) is one of the most lethal malignancies of skin [<xref ref-type="bibr" rid="CR1">1</xref>]. It was estimated that 287,700 new cases of melanoma and 60,700 deaths of melanomas occurred worldwide in 2018 [<xref ref-type="bibr" rid="CR2">2</xref>]. Patients with metastatic melanoma have a shorter long-term survival time. Moreover, survival outcomes can vary widely among patients even within the same stage due to the biological heterogeneity of melanoma. At present, the methods commonly used in the treatment of melanoma include surgical resection, chemotherapy and immunotherapy. Only a few patients with advanced melanoma have a persistent response to surgical resection and chemotherapy. Some researchers have used mouse models to analyze the causes of drug resistance, possibly due to changes in metabolic levels in the state of obesity [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Weight control can improve the effectiveness of medications and help reduce melanoma metastasis [<xref ref-type="bibr" rid="CR5">5</xref>]. In addition, the combination of chemotherapy drugs may improve drug resistance [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, because of the molecular heterogeneity, not all the melanoma patients responded well to the treatments. Mutant BRAF has been shown to be significantly associated with worsen overall survival and metastasis free survival of melanoma [<xref ref-type="bibr" rid="CR8">8</xref>], meanwhile mutant BRAF has been also proven to be a good therapeutic target for melanoma, but the resistance of small molecule drugs against mutant BRAF for melanoma is invariably observed [<xref ref-type="bibr" rid="CR9">9</xref>]. Therefore, it is imperative to develop novel prognostic biomarkers for risk stratification and treatment optimization in melanoma patients. The specific and novel biomarker may provide the opportunities for guidance of personalized therapeutic interventions and new therapeutic target development.</p>
    <p id="Par18">High-throughput RNA-sequencing (RNA-Seq) has been shown to successfully measure gene expression, discover novel transcripts and identify differentially expressed genes [<xref ref-type="bibr" rid="CR10">10</xref>]. BRAF and NRAS mutations have been used as molecular biomarkers in evaluating the clinical course of melanoma. Identification of novel molecular biomarkers becomes an area of interests to clinicians and researchers. Ideally, prognostic biomarkers are sensitive, specific, reliable, rapidly analyzable and cost effective. To date, a number of prognostic biomarkers have been proposed in melanoma [<xref ref-type="bibr" rid="CR11">11</xref>]; however, most of these putative biomarkers lack independent validation in multiple cohorts. Mining available transcriptome data with appropriate clinical follow-up information offers opportunities to prescreen and validate new prognostic biomarkers [<xref ref-type="bibr" rid="CR12">12</xref>]. Currently, there are several web-browsers, such as PRECOG [<xref ref-type="bibr" rid="CR13">13</xref>], KM plotter [<xref ref-type="bibr" rid="CR14">14</xref>] and CaPSSA [<xref ref-type="bibr" rid="CR15">15</xref>], which have provided survival analysis based on gene expression. However, most of these prognostic analysis web servers only provide data from TCGA, without data from other sources such as GEO and published literatures. As we all know, the most important and difficult part of the biomarker development is to validate the performance of potential biomarker in multiple independent datasets, in this current study, we developed an Online consensus Survival webserver for Skin Cutaneous Melanoma, named <italic>OSskcm</italic>, which analyzes tumor gene expression profiles and clinical follow-up information of 1085 melanoma patients from multiple independent cohorts. The <italic>OSskcm</italic> webserver is registration-free and can assist biologists and clinicians to evaluate the prognostic potency of genes of interests and identify potential therapeutic targets.</p>
  </sec>
  <sec id="Sec2">
    <title>Materials and methods</title>
    <p id="Par19">Expression profiling and clinical follow-up data used in <italic>OSskcm</italic> were collected from Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) and The Cancer Genome Atlas (TCGA; <ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>) by searching with the keywords of “cutaneous melanoma” and “survival”. Only datasets containing mRNA expression profiling data, clinical survival information, and at least 20 cutaneous melanoma cases were included. The Kaplan–Meier (KM) survival curves were set up using a central server, Hazard ratio (HR) and 95% confidence interval (95%CI) were calculated in a univariate Cox regression analysis. Risk factors, including race, stage, gender, age and type of therapy, can be selected for a subgroup analysis. The <italic>OSskcm</italic> is hosted in a windows tomcat server. Server-side scripts were developed in Java script, which control the request of analysis and return the analysis results. The database system is managed by a SQL Server, which integrates gene expression data and clinical data. The central server for <italic>OSskcm</italic> can be accessed at <ext-link ext-link-type="uri" xlink:href="http://bioinfo.henu.edu.cn/Melanoma/MelanomaList.jsp">http://bioinfo.henu.edu.cn/Melanoma/MelanomaList.jsp</ext-link>. More details of the methods of <italic>OSskcm</italic> development have been described [<xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR19">19</xref>].</p>
  </sec>
  <sec id="Sec3">
    <title>Results</title>
    <sec id="Sec4">
      <title>Clinical characteristics of cutaneous melanoma cohorts in <italic>OSskcm</italic></title>
      <p id="Par20">We collected 1085 unique patients, including 615 patients from six GEO datasets and 470 patients from TCGA dataset. These melanoma samples include 221 primary cutaneous melanomas, 851 metastatic melanomas, and the tumor origin of 13 patients was unknown. (Table <xref rid="Tab1" ref-type="table">1</xref>). The median age of patients is 59 years old. 762 patients have overall survival (OS) data, and the median overall survival is 39.3 months. In addition, 475 patients have progression-free survival (PFS) data, 665 patients have disease-specific survival (DSS) data, 470 patients have progression-free interval (PFI) data, and 150 patients have distant metastasis-free survival (DMFS) data.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical properties of cutaneous melanoma patients in <italic>OSskcm</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">GEO ID</th><th align="left">References</th><th align="left">Platform</th><th align="left">No. of samples</th><th align="left">Death event</th><th align="left">Median overall survival (months)</th><th align="left">Ages (years)</th><th align="left">Gender (male/female)</th><th align="left">Primary/metastatic</th><th align="left">Stage (I/II/III/IV)</th></tr></thead><tbody><tr><td align="left">GSE17275</td><td align="left">[<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">GPL1930</td><td char="." align="char">60</td><td char="." align="char">41</td><td char="(" align="char">64.00 (46.25–89.50)</td><td align="left">NA</td><td align="left">NA</td><td align="left">20/40</td><td align="left">2/8/19/31</td></tr><tr><td align="left">GSE22155</td><td align="left">[<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="left"><p>GPL6102</p><p>GPL6947</p></td><td char="." align="char">70</td><td char="." align="char">60</td><td char="(" align="char">7.27 (2.10–13.80)</td><td align="left">56.63 ± 14.58</td><td align="left">39/31</td><td align="left">0/70</td><td align="left">0/0/3/67</td></tr><tr><td align="left">GSE46517</td><td align="left">[<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="left">GPL96</td><td char="." align="char">84</td><td char="." align="char">40</td><td char="(" align="char">71 (55–89)<sup>a</sup></td><td align="left">77.03 ± 26.37</td><td align="left">39/24<sup>c</sup></td><td align="left">31/53</td><td align="left">12/15/11/24</td></tr><tr><td align="left">GSE50509</td><td align="left">[<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="left">GPL10558</td><td char="." align="char">19</td><td char="." align="char">15</td><td char="(" align="char">18.11 (8.63–26.53)</td><td align="left">57.68 ± 15.49</td><td align="left">12/7</td><td align="left">0/19</td><td align="left">NA</td></tr><tr><td align="left">GSE65904</td><td align="left">[<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="left">GPL10558</td><td char="." align="char">214</td><td char="." align="char">102</td><td char="(" align="char">17.80 (7.03–41.83)<sup>b</sup></td><td align="left">62.35 ± 14.40</td><td align="left">124/89<sup>‡</sup></td><td align="left">16/188<sup>‡</sup></td><td align="left">NA</td></tr><tr><td align="left">GSE98394</td><td align="left">[<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="left">GPL16791</td><td char="." align="char">51</td><td char="." align="char">18</td><td char="(" align="char">93.50 (35.00–111.00)</td><td align="left">NA</td><td align="left">31/20</td><td align="left">51/0</td><td align="left">12/22/10/0<sup>‡</sup></td></tr><tr><td align="left">GSE19234</td><td align="left">[<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">GPL570</td><td char="." align="char">38</td><td char="." align="char">24</td><td char="(" align="char">38.08 (23.57–65.90)</td><td align="left">62.66 ± 17.86</td><td align="left">24/14</td><td align="left">0/38</td><td align="left">0/0/34/4</td></tr><tr><td align="left">GSE53118</td><td align="left">[<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="left">GPL6884</td><td char="." align="char">79</td><td char="." align="char">47</td><td char="(" align="char">79.74 (28.81–120.05)</td><td align="left">55.49 ± 15.27</td><td align="left">50/29</td><td align="left">0/79</td><td align="left">0/0/79/0</td></tr><tr><td align="left">TCGA</td><td align="left">[<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left"><p>Illumina</p><p>HiSeqV2</p></td><td char="." align="char">470</td><td char="." align="char">216</td><td char="(" align="char">34.45 (14.90–75.17)</td><td align="left">58.22 ± 15.73</td><td align="left">290/180</td><td align="left">103/364<sup>‡</sup></td><td align="left">77/140/171/23<sup>‡</sup></td></tr><tr><td align="left">Total</td><td align="left"/><td align="left"/><td char="." align="char">1085</td><td char="." align="char">563</td><td char="(" align="char">39.30 (15.92–88.00)</td><td align="left">59.14 ± 15.55</td><td align="left">609/394</td><td align="left">221/851</td><td align="left">131/215/268/149</td></tr></tbody></table><table-wrap-foot><p><italic>NA</italic> not available</p><p><sup>a</sup>The survival endpoint was defined as event-free survival from resection until death</p><p><sup>b</sup>The survival endpoint was defined as disease-specific survival</p><p><sup>c</sup>Partial data missing</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec5">
      <title>The application of <italic>OSskcm</italic> webserver</title>
      <p id="Par21">To apply <italic>OSskcm</italic> to determine the prognostic value of gene of interest, users only need to input an official gene symbol into “Gene symbol” dialog box, and choose “Data source” as either one individual dataset or combined datasets, then select one of the “Survival” terms such as OS, PFS, DSS or PFI, and select a appropriate cut-off value of gene expression stratification by “Split patients by”. After then click the ‘Kaplan–Meier plot’ button, the KM plots with log-rank <italic>P</italic> value and HR with 95%CI will be shown on the output web page (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). If users are interested in the prognostic significance of biomarkers in a particular subgroup of patients, such as races, tumor stages and treatment methods, they may select corresponding risk factors to filter the patients prior to Kaplan–Meier analysis.<fig id="Fig1"><label>Fig. 1</label><caption><p>The usage and output web page of <italic>OSskcm</italic> webserver</p></caption><graphic xlink:href="12935_2020_1262_Fig1_HTML" id="MO1"/></fig></p>
    </sec>
    <sec id="Sec6">
      <title>Validation of previously published cutaneous melanoma biomarkers</title>
      <p id="Par22">A PubMed search was performed using keywords of ‘cutaneous melanoma’, ‘survival’, and ‘biomarker’ to identify genes previously reported as prognostic biomarkers for cutaneous melanoma in the literatures. In total, 30 such prognostic genes were validated in <italic>OSskcm</italic> (listed in Table <xref rid="Tab2" ref-type="table">2</xref>). These biomarker candidates were generally detected by tissue-based immunohistochemistry or immunofluorescent staining.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Performance of previously published protein prognostic biomarker candidates in <italic>OSskcm</italic></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Gene symbol</th><th align="left" colspan="4">Literature data</th><th align="left" colspan="4">Validation results</th></tr><tr><th align="left">References</th><th align="left"><italic>n</italic></th><th align="left">Survival endpoint</th><th align="left">Prognostic significance of high expression</th><th align="left"><italic>HR</italic> (95%CI)</th><th align="left">Log-rank <italic>P</italic> value</th><th align="left">Datasets</th><th align="left">Cut off</th></tr></thead><tbody><tr><td align="left"><italic>KLK7</italic></td><td align="left">[<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="left">45</td><td align="left">OS</td><td align="left">Good</td><td align="left">2.65 (1.27–5.53)<sup>†</sup></td><td align="left">0.0095</td><td align="left">GSE17275</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.60 (1.48–8.80)<sup>†</sup></td><td align="left">0.0049</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.93 (1.40–2.65)<sup>†</sup></td><td align="left">&lt; 0.0001</td><td align="left">TCGA</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>MITF</italic></td><td align="left">[<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">200</td><td align="left">OS</td><td align="left">Poor</td><td align="left">1.43 (1.09–1.87)<sup>†</sup></td><td align="left">0.0104</td><td align="left">TCGA</td><td align="left">Upper 50%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.46 (1.42–8.42)<sup>†</sup></td><td align="left">0.0063</td><td align="left">GSE19234</td><td align="left">Upper 50%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.33 (1.18–9.41)<sup>†</sup></td><td align="left">0.0230</td><td align="left">GSE98394</td><td align="left">Upper 50%</td></tr><tr><td align="left"><italic>KIF20A</italic></td><td align="left">[<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">61</td><td align="left">RFS</td><td align="left">Poor</td><td align="left">2.17 (1.12–4.20)<sup>†</sup></td><td align="left">0.0218</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.56 (1.20–5.47)<sup>†</sup></td><td align="left">0.0151</td><td align="left">GSE50509</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.21 (1.26–8.20)<sup>†</sup></td><td align="left">0.0147</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.44 (1.02–5.83)<sup>†</sup></td><td align="left">0.0454</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>CTHRC1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="left">35</td><td align="left">OS</td><td align="left">Poor</td><td align="left">3.41 (1.31–8.89)<sup>†</sup></td><td align="left">0.0122</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>TFAP2A</italic></td><td align="left">[<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">Nearly 600</td><td align="left">DSS</td><td align="left">Poor</td><td align="left">1.59 (1.03–2.47)<sup>‡</sup></td><td align="left">0.0379</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>ATF2</italic></td><td align="left">[<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">544</td><td align="left">OS</td><td align="left">Poor</td><td align="left">3.05 (1.56–5.97)<sup>†</sup></td><td align="left">0.0012</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>NCOA3</italic></td><td align="left">[<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">343</td><td align="left">RFS and DSS</td><td align="left">Poor</td><td align="left">1.79 (1.17–2.74)<sup>‡</sup></td><td align="left">0.0071</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>BCL2</italic></td><td align="left">[<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">339</td><td align="left">OS</td><td align="left">Good</td><td align="left">0.21 (0.04–0.97)<sup>†</sup></td><td align="left">0.0458</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>BIRC5</italic></td><td align="left">[<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">50</td><td align="left">DFS and OS</td><td align="left">Poor</td><td align="left">3.73 (1.44–9.67)<sup>†</sup></td><td align="left">0.0068</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>MCAM</italic></td><td align="left">[<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="left">76</td><td align="left">OS</td><td align="left">Poor</td><td align="left">4.66 (1.78–12.18)<sup>†</sup></td><td align="left">0.0017</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>PLAT</italic></td><td align="left">[<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="left">214</td><td align="left">DMFI and OS</td><td align="left">Poor</td><td align="left">2.24 (1.16–4.34)<sup>†</sup></td><td align="left">0.0164</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.88 (1.47–10.24)<sup>†</sup></td><td align="left">0.0063</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>NOS2</italic></td><td align="left">[<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="left">132</td><td align="left">DSS and OS</td><td align="left">Poor</td><td align="left">1.41 (1.07–1.85)<sup>†</sup></td><td align="left">0.0131</td><td align="left">TCGA</td><td align="left">Upper 50%</td></tr><tr><td align="left"><italic>CDKN1B</italic></td><td align="left">[<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="left">383</td><td align="left">DSS and OS</td><td align="left">Poor</td><td align="left">0.48 (0.24–0.95)<sup>†</sup></td><td align="left">0.0341</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">0.69 (0.50–0.95)<sup>†</sup></td><td align="left">0.0235</td><td align="left">TCGA</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>BCL6</italic></td><td align="left">[<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="left">88</td><td align="left">6-year OS</td><td align="left">Poor</td><td align="left">0.57 (0.40–0.80)<sup>†</sup></td><td align="left">0.0011</td><td align="left">TCGA</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>FXYD5</italic></td><td align="left">[<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">115</td><td align="left">OS</td><td align="left">Poor</td><td align="left">3.10 (1.24–7.76)<sup>†</sup></td><td align="left">0.0159</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>DDIT3</italic></td><td align="left">[<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">106</td><td align="left">OS</td><td align="left">Good</td><td align="left">5.74 (2.18–15.13)<sup>†</sup></td><td align="left">0.0004</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>MCAT</italic></td><td align="left">[<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">1270</td><td align="left">DFI and OS</td><td align="left">Poor</td><td align="left">5.75 (1.26–26.10)<sup>†</sup></td><td align="left">0.0236</td><td align="left">GSE22155</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">4.51 (1.72–11.82)<sup>†</sup></td><td align="left">0.0021</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>CTNNB1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">202</td><td align="left">DSS</td><td align="left">Good</td><td align="left">1.55 (1.02–2.37)<sup>‡</sup></td><td align="left">0.0412</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.75 (1.15–2.67)<sup>‡</sup></td><td align="left">0.0088</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>AKT1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR46">46</xref>]</td><td align="left">222</td><td align="left">5-year DSS or OS</td><td align="left">Poor</td><td align="left">6.41 (2.39–17.23)<sup>†</sup></td><td align="left">0.0002</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">1.53 (1.13–2.06)<sup>†</sup></td><td align="left">0.0056</td><td align="left">TCGA</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>RUNX3</italic></td><td align="left">[<xref ref-type="bibr" rid="CR47">47</xref>]</td><td align="left">421</td><td align="left">5-year OS</td><td align="left">Good</td><td align="left">3.75 (1.36–10.33)<sup>†</sup></td><td align="left">0.0107</td><td align="left">GSE50509</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left">5-year DSS</td><td align="left"/><td align="left">1.81 (1.18–2.76)<sup>‡</sup></td><td align="left">0.0062</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>BBC3</italic></td><td align="left">[<xref ref-type="bibr" rid="CR48">48</xref>]</td><td align="left">158</td><td align="left">5-year DSS or OS</td><td align="left">Poor</td><td align="left">3.62 (1.38–9.52)<sup>†</sup></td><td align="left">0.0092</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>MMP2</italic></td><td align="left">[<xref ref-type="bibr" rid="CR49">49</xref>]</td><td align="left">157</td><td align="left">DSS and RFS</td><td align="left">Poor</td><td align="left">1.41 (1.06–1.89)<sup>‡</sup></td><td align="left">0.0197</td><td align="left">TCGA</td><td align="left">Upper 50%</td></tr><tr><td align="left"><italic>SPP1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR50">50</xref>]</td><td align="left">345</td><td align="left">RFS</td><td align="left">Poor</td><td align="left">9.42 (3.46–25.67)<sup>†</sup></td><td align="left">&lt; 0.0001</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>TNC</italic></td><td align="left">[<xref ref-type="bibr" rid="CR51">51</xref>]</td><td align="left">98</td><td align="left">DFS</td><td align="left">Poor</td><td align="left">1.54 (1.01–2.34)<sup>‡</sup></td><td align="left">0.0434</td><td align="left">GSE65904</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>CCNA2</italic></td><td align="left">[<xref ref-type="bibr" rid="CR52">52</xref>]</td><td align="left">245</td><td align="left">RFS</td><td align="left">Poor</td><td align="left">2.23 (1.02–4.88)<sup>†</sup></td><td align="left">0.0437</td><td align="left">GSE50509</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>RGS1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR53">53</xref>]</td><td align="left">40</td><td align="left">DSS</td><td align="left">Poor</td><td align="left">2.74 (1.03–7.24)<sup>†</sup></td><td align="left">0.0425</td><td align="left">GSE98394</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">3.24 (1.31–8.00)<sup>†</sup></td><td align="left">0.0110</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">2.66 (1.07–6.65)<sup>†</sup></td><td align="left">0.0357</td><td align="left">GSE19234</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>SPARC</italic></td><td align="left">[<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">112</td><td align="left">DFS</td><td align="left">Poor</td><td align="left">2.78 (1.21–6.34)<sup>†</sup></td><td align="left">0.0154</td><td align="left">GSE50509</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>CXCR4</italic></td><td align="left">[<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">71</td><td align="left">DFS and OS</td><td align="left">Poor</td><td align="left">0.70 (0.51–0.97)<sup>†</sup></td><td align="left">0.0315</td><td align="left">TCGA</td><td align="left">Upper 25%</td></tr><tr><td align="left"><italic>RBM3</italic></td><td align="left">[<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">246</td><td align="left">OS</td><td align="left">Good</td><td align="left">NS</td><td align="left">NS</td><td align="left">–</td><td align="left">–</td></tr><tr><td align="left"><italic>EPAS1</italic></td><td align="left">[<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">46</td><td align="left">DSS</td><td align="left">Poor</td><td align="left">3.51 (1.56–7.91)<sup>†</sup></td><td align="left">0.0024</td><td align="left">GSE50509</td><td align="left">Upper 25%</td></tr></tbody></table><table-wrap-foot><p><italic>NS</italic> not significance, <italic>RFS</italic> recurrence-free survival, <italic>DFS</italic> disease-specific survival, <italic>DFI</italic> disease-free interval, <italic>DMFI</italic> distant metastasis-free interval</p><p><sup>†,‡</sup><italic>HR</italic> (95%CI) and Log-rank <italic>P</italic> value of overall survival (OS) and disease-specific survival (DSS)</p></table-wrap-foot></table-wrap></p>
      <p id="Par23">The analysis of these reported prognostic biomarkers in <italic>OSskcm</italic> showed that the prognostic roles of 22 genes were consistent with previous findings, <italic>RBM3</italic> gene had no statistically significance on prognosis, and the other 7 genes (<italic>KLK7</italic>, <italic>CXCR4</italic>, <italic>CDKN1B</italic>, <italic>BCL6</italic>, <italic>CTNNB1</italic>, <italic>RUNX3</italic> and <italic>DDIT3</italic>) had opposite prognostic trends compared to literatures. The analysis results were presented in Table <xref rid="Tab2" ref-type="table">2</xref>.</p>
    </sec>
    <sec id="Sec7">
      <title>Screening of new prognostic biomarkers for cutaneous melanoma</title>
      <p id="Par24"><italic>OSskcm</italic> can also be used to screen novel prognostic biomarkers for cutaneous melanoma, where OS, DSS, PFS, PFI and DMFS can be investigated. By <italic>OSskcm</italic>, we found that high expression of <italic>SAE1</italic> gene is associated with poor prognosis of cutaneous melanoma (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), and the prognostic potency of <italic>SAE1</italic> gene has not been previously reported in cutaneous melanoma.<fig id="Fig2"><label>Fig. 2</label><caption><p><italic>SAE1</italic> is identified as an unfavorable prognostic biomarker in <italic>OSskcm</italic>. Overall survival (OS) curve of cutaneous melanoma patients based on TCGA (<bold>a</bold>), GSE19234 (<bold>b</bold>), GSE22155 (<bold>c</bold>) and GSE98394 (<bold>d</bold>) data. Upper 25%: the SKCM cases with ranked top 25% higher expression level for the inputted gene; Other 75%: the SKCM cases with ranked bottom 75% lower expression level of the inputted gene</p></caption><graphic xlink:href="12935_2020_1262_Fig2_HTML" id="MO2"/></fig></p>
    </sec>
  </sec>
  <sec id="Sec8">
    <title>Discussion</title>
    <p id="Par25">Due to the variant prognosis of cutaneous melanoma patients, the development of molecular prognosis biomarkers is significant. Here, we collected multiple large transcriptomic datasets to increase the statistical power for analyzing the association between the investigated marker and survival rate, and developed a freely accessible webserver <italic>OSskcm</italic> to estimate the prognostic value of any inputted gene in a large cohort of patients, by which KM survival curves as well as HR and log-rank <italic>P</italic> values could be outputted and presented. <italic>OSskcm</italic> is a webserver that can mutually validate prognostic biomarkers of cutaneous melanoma in multiple data sets. A total of 1085 patients of cutaneous melanoma with RNA-seq data from clinical tissues and clinical information were included in <italic>OSskcm</italic>. In addition, risk factors, including race, stage, gender, age and therapy type, can be selected for subgroup analysis. Clinical outcome data of OS, PFS, DSS, PFI, and DMFS was included in analysis.</p>
    <p id="Par26">We tested the performance of <italic>OSskcm</italic> using 30 previously reported cutaneous melanoma prognostic biomarkers. Among these, 22 genes were validated in <italic>OSskcm</italic>, but the prognostic significance of <italic>RBM3</italic>, <italic>KLK7, CXCR4</italic>, <italic>CDKN1B</italic>, <italic>BCL6</italic>, <italic>CTNNB1</italic>, <italic>RUNX3</italic> and <italic>DDIT3</italic> genes were inconsistent between literatures and <italic>OSskcm</italic>. It may be because the <italic>OSskcm</italic> utilizes mRNA expression data while all previously published biomarkers were studied based on the protein level. It is known that there is an inconsistency between the levels of mRNA and protein due to intracellular modifications, such as post-transcriptional regulation, protein translation and post-translational regulation. In addition, the prognostic significance of a protein may be determined by its subcellular localization. For example, loss of nuclear CDKN1B expression is correlated with a worse 5-year survival of primary melanoma patients in Kaplan–Meier analysis, but gain of cytoplasmic CDKN1B was associated with a poor 5-year survival of metastatic melanoma patients.</p>
    <p id="Par27"><italic>KIF20A</italic> and <italic>RGS1</italic> genes have been reported to play critical roles in the development and progression of cancer, and promote the proliferation, migration and invasion of cancer cells [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>]. In <italic>OSskcm</italic>, <italic>KIF20A</italic> and <italic>RGS1</italic> were found to be strongly associated with cutaneous melanoma prognosis. In addition, we found that <italic>SAE1</italic> could be a new prognostic biomarker in cutaneous melanoma. <italic>SAE1</italic> is dimeric SUMO Activating Enzyme E1, involves in SUMO conjugation [<xref ref-type="bibr" rid="CR60">60</xref>]. Breast cancer patients with lower <italic>SAE1</italic> expression have been reported to have significantly lower instances of metastatic cancer and increased survival compared to those that express a higher level of <italic>SAE1</italic> [<xref ref-type="bibr" rid="CR61">61</xref>]. Moreover, <italic>SAE1</italic> was reported to have the strongest synthetic lethal interactions with K-Ras and can be used to evaluate the aggressiveness of mutated K-Ras-dependent malignancies [<xref ref-type="bibr" rid="CR62">62</xref>]. It will be interesting to further verify by experiments whether <italic>SAE1</italic> gene could be a new prognostic biomarker in cutaneous melanoma.</p>
  </sec>
  <sec id="Sec9">
    <title>Conclusion</title>
    <p id="Par28">In summary, by utilizing genome-wide microarray datasets and RNAseq datasets, we built a prognosis webserver, <italic>OSskcm</italic>, which offer a platform for biologists and clinicians to identify prognostic biomarkers for cutaneous melanoma. Additional more research regarding how to better translate our web server and web server derived biomarkers for practice from local to global health is required [<xref ref-type="bibr" rid="CR63">63</xref>].</p>
  </sec>
</body>
<back>
  <glossary>
    <title>Abbreviations</title>
    <def-list>
      <def-item>
        <term>
          <italic>OSskcm</italic>
        </term>
        <def>
          <p id="Par5">Online consensus Survival webserver for Skin Cutaneous Melanoma</p>
        </def>
      </def-item>
      <def-item>
        <term>GEO</term>
        <def>
          <p id="Par6">Gene Expression Omnibus</p>
        </def>
      </def-item>
      <def-item>
        <term>TCGA</term>
        <def>
          <p id="Par7">The Cancer Genome Atlas</p>
        </def>
      </def-item>
      <def-item>
        <term>OS</term>
        <def>
          <p id="Par8">Overall survival</p>
        </def>
      </def-item>
      <def-item>
        <term>PFS</term>
        <def>
          <p id="Par9">Progression-free survival</p>
        </def>
      </def-item>
      <def-item>
        <term>DSS</term>
        <def>
          <p id="Par10">Disease-specific survival</p>
        </def>
      </def-item>
      <def-item>
        <term>PFI</term>
        <def>
          <p id="Par11">Progression-free interval</p>
        </def>
      </def-item>
      <def-item>
        <term>DMFS</term>
        <def>
          <p id="Par12">Distant metastasis-free survival</p>
        </def>
      </def-item>
      <def-item>
        <term>RFS</term>
        <def>
          <p id="Par13">Recurrence-free survival</p>
        </def>
      </def-item>
      <def-item>
        <term>DFS</term>
        <def>
          <p id="Par14">Disease-specific survival</p>
        </def>
      </def-item>
      <def-item>
        <term>DFI</term>
        <def>
          <p id="Par15">Disease-free interval</p>
        </def>
      </def-item>
      <def-item>
        <term>DMFI</term>
        <def>
          <p id="Par16">Distant metastasis-free interval</p>
        </def>
      </def-item>
    </def-list>
  </glossary>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher's Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Lu Zhang and Qiang Wang contributed equally to this study</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>Not applicable.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>All authors materially participated in the study and manuscript preparation. XQG, LZ and QW participated in the design and the conception of the study. LJW, ZHL, XCZ, PPT and XZH collected and managed data. XQG, LZ and QW developed methods and performed data analysis. QW built the webserver. YQL provided technical support. LZ and QW wrote the original draft. LXX, YA, GSZ, WZ and XQG reviewed and edited the manuscript. XQG supervised the research process. All authors read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>This study was supported by National Natural Science Foundation of China (No. 81602362), Program for Innovative Talents of Science and Technology in Henan Province (No. 18HASTIT048), Kaifeng Science and Technology Major Project (18ZD008), Supporting grant of Bioinformatics Center of Henan University (No. 2018YLJC01; No. 2019YLXKJC01), Student Innovation and Entrepreneurship Training Program of Henan University (No. 2019101905).</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The datasets used and analyzed during the current study are available from Gene Expression Omnibus (GEO; <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) and The Cancer Genome Atlas (TCGA; <ext-link ext-link-type="uri" xlink:href="https://cancergenome.nih.gov/">https://cancergenome.nih.gov/</ext-link>).</p>
  </notes>
  <notes id="FPar1">
    <title>Ethics approval and consent to participate</title>
    <p id="Par29">Not applicable.</p>
  </notes>
  <notes id="FPar2">
    <title>Consent for publication</title>
    <p id="Par30">We have obtained consents to publish this paper from all participants of this study.</p>
  </notes>
  <notes id="FPar3" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par31">The authors declare that they have no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schadendorf</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>van Akkooi</surname>
            <given-names>ACJ</given-names>
          </name>
          <name>
            <surname>Berking</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Griewank</surname>
            <given-names>KG</given-names>
          </name>
          <name>
            <surname>Gutzmer</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hauschild</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Melanoma</article-title>
        <source>Lancet</source>
        <year>2018</year>
        <volume>392</volume>
        <issue>10151</issue>
        <fpage>971</fpage>
        <lpage>984</lpage>
        <?supplied-pmid 30238891?>
        <pub-id pub-id-type="pmid">30238891</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferlay</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Colombet</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Soerjomataram</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Mathers</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Parkin</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Pineros</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods</article-title>
        <source>Int J Cancer</source>
        <year>2019</year>
        <volume>144</volume>
        <issue>8</issue>
        <fpage>1941</fpage>
        <lpage>1953</lpage>
        <?supplied-pmid 30350310?>
        <pub-id pub-id-type="pmid">30350310</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malvi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chaube</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Mohammad</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Vijayakumar</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Elevated circulatory levels of leptin and resistin impair therapeutic efficacy of dacarbazine in melanoma under obese state</article-title>
        <source>Cancer Metab.</source>
        <year>2018</year>
        <volume>6</volume>
        <fpage>2</fpage>
        <?supplied-pmid 29568521?>
        <pub-id pub-id-type="pmid">29568521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malvi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chaube</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pandey</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Vijayakumar</surname>
            <given-names>MV</given-names>
          </name>
          <name>
            <surname>Boreddy</surname>
            <given-names>PR</given-names>
          </name>
          <name>
            <surname>Mohammad</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Obesity induced rapid melanoma progression is reversed by orlistat treatment and dietary intervention: role of adipokines</article-title>
        <source>Mol Oncol.</source>
        <year>2015</year>
        <volume>9</volume>
        <issue>3</issue>
        <fpage>689</fpage>
        <lpage>703</lpage>
        <?supplied-pmid 25499031?>
        <pub-id pub-id-type="pmid">25499031</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malvi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Chaube</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Mohammad</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Pandey</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Vijayakumar</surname>
            <given-names>MV</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance</article-title>
        <source>Cancer Metab.</source>
        <year>2016</year>
        <volume>4</volume>
        <fpage>21</fpage>
        <?supplied-pmid 27980732?>
        <pub-id pub-id-type="pmid">27980732</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chaube</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Malvi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Mohammad</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Meena</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Bhat</surname>
            <given-names>MK</given-names>
          </name>
        </person-group>
        <article-title>Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression</article-title>
        <source>Oncotarget.</source>
        <year>2015</year>
        <volume>6</volume>
        <issue>35</issue>
        <fpage>37281</fpage>
        <lpage>37299</lpage>
        <?supplied-pmid 26484566?>
        <pub-id pub-id-type="pmid">26484566</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mohammad</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Malvi</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Meena</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Chaube</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Vannuruswamy</surname>
            <given-names>G</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma</article-title>
        <source>Mol Cancer.</source>
        <year>2014</year>
        <volume>13</volume>
        <fpage>204</fpage>
        <?supplied-pmid 25178635?>
        <pub-id pub-id-type="pmid">25178635</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Moreau</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Saiag</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Aegerter</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bosset</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Longvert</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Helias-Rodzewicz</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prognostic value of BRAF(V<sup>600</sup>) mutations in melanoma patients after resection of metastatic lymph nodes</article-title>
        <source>Ann Surg Oncol</source>
        <year>2012</year>
        <volume>19</volume>
        <issue>13</issue>
        <fpage>4314</fpage>
        <lpage>4321</lpage>
        <?supplied-pmid 22772867?>
        <pub-id pub-id-type="pmid">22772867</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Heynen</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Prahallad</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Robert</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma</article-title>
        <source>Nature</source>
        <year>2014</year>
        <volume>508</volume>
        <issue>7494</issue>
        <fpage>118</fpage>
        <lpage>122</lpage>
        <?supplied-pmid 24670642?>
        <pub-id pub-id-type="pmid">24670642</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Comparative transcriptome analyses of drought-resistant and—susceptible <italic>Brassica napus</italic> L. and development of EST-SSR markers by RNA-Seq</article-title>
        <source>J Plant Biol.</source>
        <year>2015</year>
        <volume>58</volume>
        <fpage>259</fpage>
        <lpage>269</lpage>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Abbas</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Bhawan</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers</article-title>
        <source>Am J Dermatopathol</source>
        <year>2014</year>
        <volume>36</volume>
        <issue>5</issue>
        <fpage>363</fpage>
        <lpage>379</lpage>
        <?supplied-pmid 24803061?>
        <pub-id pub-id-type="pmid">24803061</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients</article-title>
        <source>Genes</source>
        <year>2019</year>
        <volume>10</volume>
        <issue>1</issue>
        <fpage>36</fpage>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gentles</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Newman</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Bratman</surname>
            <given-names>SV</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title>
        <source>Nat Med</source>
        <year>2015</year>
        <volume>21</volume>
        <issue>8</issue>
        <fpage>938</fpage>
        <lpage>945</lpage>
        <?supplied-pmid 26193342?>
        <pub-id pub-id-type="pmid">26193342</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Szasz</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Lanczky</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nagy</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Forster</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hark</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>JE</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients</article-title>
        <source>Oncotarget.</source>
        <year>2016</year>
        <volume>7</volume>
        <issue>31</issue>
        <fpage>49322</fpage>
        <lpage>49333</lpage>
        <?supplied-pmid 27384994?>
        <pub-id pub-id-type="pmid">27384994</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Seo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>CaPSSA: visual evaluation of cancer biomarker genes for patient stratification and survival analysis using mutation and expression data</article-title>
        <source>Bioinformatics.</source>
        <year>2019</year>
        <volume>35</volume>
        <issue>24</issue>
        <fpage>5341</fpage>
        <lpage>5343</lpage>
        <?supplied-pmid 31228188?>
        <pub-id pub-id-type="pmid">31228188</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>OSlms: a web server to evaluate the prognostic value of genes in leiomyosarcoma</article-title>
        <source>Front Oncol.</source>
        <year>2019</year>
        <volume>9</volume>
        <fpage>190</fpage>
        <?supplied-pmid 30984618?>
        <pub-id pub-id-type="pmid">30984618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>OSblca: a web server for investigating prognostic biomarkers of bladder cancer patients</article-title>
        <source>Front Oncol.</source>
        <year>2019</year>
        <volume>9</volume>
        <fpage>466</fpage>
        <?supplied-pmid 31275847?>
        <pub-id pub-id-type="pmid">31275847</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Xie</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Nan</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>OSacc: gene expression-based survival analysis web tool for adrenocortical carcinoma</article-title>
        <source>Cancer Manag Res.</source>
        <year>2019</year>
        <volume>11</volume>
        <fpage>9145</fpage>
        <lpage>9152</lpage>
        <?supplied-pmid 31749633?>
        <pub-id pub-id-type="pmid">31749633</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Ge</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>An</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>OSuvm: an interactive online consensus survival tool for uveal melanoma prognosis analysis</article-title>
        <source>Mol Carcinog</source>
        <year>2020</year>
        <volume>59</volume>
        <issue>1</issue>
        <fpage>56</fpage>
        <lpage>61</lpage>
        <?supplied-pmid 31646691?>
        <pub-id pub-id-type="pmid">31646691</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Esteves</surname>
            <given-names>GH</given-names>
          </name>
          <name>
            <surname>Almeida</surname>
            <given-names>OM</given-names>
          </name>
          <name>
            <surname>Rezze</surname>
            <given-names>GG</given-names>
          </name>
          <name>
            <surname>Landman</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Marques</surname>
            <given-names>SM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene network analyses point to the importance of human tissue kallikreins in melanoma progression</article-title>
        <source>BMC Med Genomics</source>
        <year>2011</year>
        <volume>4</volume>
        <fpage>76</fpage>
        <?supplied-pmid 22032772?>
        <pub-id pub-id-type="pmid">22032772</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jonsson</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Busch</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Knappskog</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Geisler</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Miletic</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ringner</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome</article-title>
        <source>Clin Cancer Res</source>
        <year>2010</year>
        <volume>16</volume>
        <issue>13</issue>
        <fpage>3356</fpage>
        <lpage>3367</lpage>
        <?supplied-pmid 20460471?>
        <pub-id pub-id-type="pmid">20460471</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kabbarah</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Nogueira</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Nazarian</surname>
            <given-names>RM</given-names>
          </name>
          <name>
            <surname>Bosenberg</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrative genome comparison of primary and metastatic melanomas</article-title>
        <source>PLoS ONE</source>
        <year>2010</year>
        <volume>5</volume>
        <issue>5</issue>
        <fpage>e10770</fpage>
        <?supplied-pmid 20520718?>
        <pub-id pub-id-type="pmid">20520718</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rizos</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Menzies</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Pupo</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Carlino</surname>
            <given-names>MS</given-names>
          </name>
          <name>
            <surname>Fung</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Hyman</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact</article-title>
        <source>Clin Cancer Res</source>
        <year>2014</year>
        <volume>20</volume>
        <issue>7</issue>
        <fpage>1965</fpage>
        <lpage>1977</lpage>
        <?supplied-pmid 24463458?>
        <pub-id pub-id-type="pmid">24463458</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cirenajwis</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Ekedahl</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Lauss</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Harbst</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Carneiro</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Enoksson</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy</article-title>
        <source>Oncotarget.</source>
        <year>2015</year>
        <volume>6</volume>
        <issue>14</issue>
        <fpage>12297</fpage>
        <lpage>12309</lpage>
        <?supplied-pmid 25909218?>
        <pub-id pub-id-type="pmid">25909218</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Badal</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Solovyov</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Di Cecilia</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>LW</given-names>
          </name>
          <name>
            <surname>Iqbal</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation</article-title>
        <source>JCI Insight.</source>
        <year>2017</year>
        <pub-id pub-id-type="doi">10.1172/jci.insight.92102</pub-id>
        <?supplied-pmid 28469092?>
        <pub-id pub-id-type="pmid">28469092</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bogunovic</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>O’Neill</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Belitskaya-Levy</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Vacic</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Adams</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival</article-title>
        <source>Proc Natl Acad Sci USA.</source>
        <year>2009</year>
        <volume>106</volume>
        <issue>48</issue>
        <fpage>20429</fpage>
        <lpage>20434</lpage>
        <?supplied-pmid 19915147?>
        <pub-id pub-id-type="pmid">19915147</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mann</surname>
            <given-names>GJ</given-names>
          </name>
          <name>
            <surname>Pupo</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Campain</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Carter</surname>
            <given-names>CD</given-names>
          </name>
          <name>
            <surname>Schramm</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Pianova</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma</article-title>
        <source>J Investig Dermatol.</source>
        <year>2013</year>
        <volume>133</volume>
        <issue>2</issue>
        <fpage>509</fpage>
        <lpage>517</lpage>
        <?supplied-pmid 22931913?>
        <pub-id pub-id-type="pmid">22931913</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Blum</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Zenklusen</surname>
            <given-names>JC</given-names>
          </name>
        </person-group>
        <article-title>SnapShot: TCGA-analyzed tumors</article-title>
        <source>Cell</source>
        <year>2018</year>
        <volume>173</volume>
        <issue>2</issue>
        <fpage>530</fpage>
        <?supplied-pmid 29625059?>
        <pub-id pub-id-type="pmid">29625059</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Garraway</surname>
            <given-names>LA</given-names>
          </name>
          <name>
            <surname>Widlund</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Rubin</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Getz</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Ramaswamy</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma</article-title>
        <source>Nature</source>
        <year>2005</year>
        <volume>436</volume>
        <issue>7047</issue>
        <fpage>117</fpage>
        <lpage>122</lpage>
        <?supplied-pmid 16001072?>
        <pub-id pub-id-type="pmid">16001072</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yamashita</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Fukushima</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jinnin</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Honda</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Makino</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sakai</surname>
            <given-names>K</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Kinesin family member 20A is a novel melanoma-associated antigen</article-title>
        <source>Acta Derm Venereol</source>
        <year>2012</year>
        <volume>92</volume>
        <issue>6</issue>
        <fpage>593</fpage>
        <lpage>597</lpage>
        <?supplied-pmid 22854760?>
        <pub-id pub-id-type="pmid">22854760</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Eriksson</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Le Joncour</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Nummela</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jahkola</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Virolainen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Laakkonen</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression</article-title>
        <source>Oncotarget.</source>
        <year>2016</year>
        <volume>7</volume>
        <issue>12</issue>
        <fpage>15065</fpage>
        <lpage>15092</lpage>
        <?supplied-pmid 26918341?>
        <pub-id pub-id-type="pmid">26918341</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berger</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Davis</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Tellez</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Prieto</surname>
            <given-names>VG</given-names>
          </name>
          <name>
            <surname>Gershenwald</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>MM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction</article-title>
        <source>Cancer Res</source>
        <year>2005</year>
        <volume>65</volume>
        <issue>23</issue>
        <fpage>11185</fpage>
        <lpage>11192</lpage>
        <?supplied-pmid 16322269?>
        <pub-id pub-id-type="pmid">16322269</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Berger</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Kluger</surname>
            <given-names>HM</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kielhorn</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Halaban</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Ronai</surname>
            <given-names>Z</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival</article-title>
        <source>Cancer Res</source>
        <year>2003</year>
        <volume>63</volume>
        <issue>23</issue>
        <fpage>8103</fpage>
        <lpage>8107</lpage>
        <?supplied-pmid 14678960?>
        <pub-id pub-id-type="pmid">14678960</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rangel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Torabian</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shaikh</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Nosrati</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Baehner</surname>
            <given-names>FL</given-names>
          </name>
          <name>
            <surname>Haqq</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma</article-title>
        <source>J Clin Oncol</source>
        <year>2006</year>
        <volume>24</volume>
        <issue>28</issue>
        <fpage>4565</fpage>
        <lpage>4569</lpage>
        <?supplied-pmid 17008696?>
        <pub-id pub-id-type="pmid">17008696</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Divito</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Berger</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Camp</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Dolled-Filhart</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rimm</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Kluger</surname>
            <given-names>HM</given-names>
          </name>
        </person-group>
        <article-title>Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma</article-title>
        <source>Cancer Res</source>
        <year>2004</year>
        <volume>64</volume>
        <issue>23</issue>
        <fpage>8773</fpage>
        <lpage>8777</lpage>
        <?supplied-pmid 15574790?>
        <pub-id pub-id-type="pmid">15574790</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Piras</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Murtas</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Minerba</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ugalde</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Floris</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Maxia</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma</article-title>
        <source>Histopathology</source>
        <year>2007</year>
        <volume>50</volume>
        <issue>7</issue>
        <fpage>835</fpage>
        <lpage>842</lpage>
        <?supplied-pmid 17543072?>
        <pub-id pub-id-type="pmid">17543072</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pacifico</surname>
            <given-names>MD</given-names>
          </name>
          <name>
            <surname>Grover</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Richman</surname>
            <given-names>PI</given-names>
          </name>
          <name>
            <surname>Daley</surname>
            <given-names>FM</given-names>
          </name>
          <name>
            <surname>Buffa</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>GD</given-names>
          </name>
        </person-group>
        <article-title>Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker</article-title>
        <source>Plast Reconstr Surg</source>
        <year>2005</year>
        <volume>115</volume>
        <issue>2</issue>
        <fpage>367</fpage>
        <lpage>375</lpage>
        <?supplied-pmid 15692338?>
        <pub-id pub-id-type="pmid">15692338</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ferrier</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Suciu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>van Geloof</surname>
            <given-names>WL</given-names>
          </name>
          <name>
            <surname>Straatman</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Eggermont</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Koops</surname>
            <given-names>HS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>High tPA-expression in primary melanoma of the limb correlates with good prognosis</article-title>
        <source>Br J Cancer</source>
        <year>2000</year>
        <volume>83</volume>
        <issue>10</issue>
        <fpage>1351</fpage>
        <lpage>1359</lpage>
        <?supplied-pmid 11044361?>
        <pub-id pub-id-type="pmid">11044361</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ekmekcioglu</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ellerhorst</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Prieto</surname>
            <given-names>VG</given-names>
          </name>
          <name>
            <surname>Johnson</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Broemeling</surname>
            <given-names>LD</given-names>
          </name>
          <name>
            <surname>Grimm</surname>
            <given-names>EA</given-names>
          </name>
        </person-group>
        <article-title>Tumor iNOS predicts poor survival for stage III melanoma patients</article-title>
        <source>Int J Cancer</source>
        <year>2006</year>
        <volume>119</volume>
        <issue>4</issue>
        <fpage>861</fpage>
        <lpage>866</lpage>
        <?supplied-pmid 16557582?>
        <pub-id pub-id-type="pmid">16557582</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Martinka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Prognostic significance of cytoplasmic p27 expression in human melanoma</article-title>
        <source>Cancer Epidemiol Biomark Prev</source>
        <year>2011</year>
        <volume>20</volume>
        <issue>10</issue>
        <fpage>2212</fpage>
        <lpage>2221</lpage>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alonso</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Ortiz</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Pollan</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Perez-Gomez</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Sanchez</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Acuna</surname>
            <given-names>MJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study</article-title>
        <source>Am J Pathol</source>
        <year>2004</year>
        <volume>164</volume>
        <issue>1</issue>
        <fpage>193</fpage>
        <lpage>203</lpage>
        <?supplied-pmid 14695333?>
        <pub-id pub-id-type="pmid">14695333</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Nishizawa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Nakanishi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yoshimura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sasajima</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Yamazaki</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Yamamoto</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients</article-title>
        <source>Cancer</source>
        <year>2005</year>
        <volume>103</volume>
        <issue>8</issue>
        <fpage>1693</fpage>
        <lpage>1700</lpage>
        <?supplied-pmid 15751018?>
        <pub-id pub-id-type="pmid">15751018</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Korabiowska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cordon-Cardo</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Betke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Schlott</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Kotthaus</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Stachura</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>GADD153 is an independent prognostic factor in melanoma: immunohistochemical and molecular genetic analysis</article-title>
        <source>Histol Histopathol</source>
        <year>2002</year>
        <volume>17</volume>
        <issue>3</issue>
        <fpage>805</fpage>
        <lpage>811</lpage>
        <?supplied-pmid 12168790?>
        <pub-id pub-id-type="pmid">12168790</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Weinlich</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Eisendle</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hassler</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Baltaci</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fritsch</surname>
            <given-names>PO</given-names>
          </name>
          <name>
            <surname>Zelger</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>Metallothionein—overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients</article-title>
        <source>Br J Cancer</source>
        <year>2006</year>
        <volume>94</volume>
        <issue>6</issue>
        <fpage>835</fpage>
        <lpage>841</lpage>
        <?supplied-pmid 16508630?>
        <pub-id pub-id-type="pmid">16508630</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bachmann</surname>
            <given-names>IM</given-names>
          </name>
          <name>
            <surname>Straume</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Puntervoll</surname>
            <given-names>HE</given-names>
          </name>
          <name>
            <surname>Kalvenes</surname>
            <given-names>MB</given-names>
          </name>
          <name>
            <surname>Akslen</surname>
            <given-names>LA</given-names>
          </name>
        </person-group>
        <article-title>Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma</article-title>
        <source>Clin Cancer Res</source>
        <year>2005</year>
        <volume>11</volume>
        <issue>24 Pt 1</issue>
        <fpage>8606</fpage>
        <lpage>8614</lpage>
        <?supplied-pmid 16361544?>
        <pub-id pub-id-type="pmid">16361544</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dai</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Martinka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases</article-title>
        <source>J Clin Oncol</source>
        <year>2005</year>
        <volume>23</volume>
        <issue>7</issue>
        <fpage>1473</fpage>
        <lpage>1482</lpage>
        <?supplied-pmid 15735123?>
        <pub-id pub-id-type="pmid">15735123</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Martinka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Prognostic significance of RUNX3 expression in human melanoma</article-title>
        <source>Cancer</source>
        <year>2011</year>
        <volume>117</volume>
        <issue>12</issue>
        <fpage>2719</fpage>
        <lpage>2727</lpage>
        <?supplied-pmid 21656750?>
        <pub-id pub-id-type="pmid">21656750</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Karst</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>DL</given-names>
          </name>
          <name>
            <surname>Martinka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>PUMA expression is significantly reduced in human cutaneous melanomas</article-title>
        <source>Oncogene</source>
        <year>2005</year>
        <volume>24</volume>
        <issue>6</issue>
        <fpage>1111</fpage>
        <lpage>1116</lpage>
        <?supplied-pmid 15690057?>
        <pub-id pub-id-type="pmid">15690057</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vaisanen</surname>
            <given-names>AH</given-names>
          </name>
          <name>
            <surname>Kallioinen</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Turpeenniemi-Hujanen</surname>
            <given-names>T</given-names>
          </name>
        </person-group>
        <article-title>Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma</article-title>
        <source>Hum Pathol</source>
        <year>2008</year>
        <volume>39</volume>
        <issue>3</issue>
        <fpage>377</fpage>
        <lpage>385</lpage>
        <?supplied-pmid 18187184?>
        <pub-id pub-id-type="pmid">18187184</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rangel</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nosrati</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Torabian</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Shaikh</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Leong</surname>
            <given-names>SP</given-names>
          </name>
          <name>
            <surname>Haqq</surname>
            <given-names>C</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Osteopontin as a molecular prognostic marker for melanoma</article-title>
        <source>Cancer</source>
        <year>2008</year>
        <volume>112</volume>
        <issue>1</issue>
        <fpage>144</fpage>
        <lpage>150</lpage>
        <?supplied-pmid 18023025?>
        <pub-id pub-id-type="pmid">18023025</pub-id>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ilmonen</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Jahkola</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Turunen</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Muhonen</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Asko-Seljavaara</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Tenascin-C in primary malignant melanoma of the skin</article-title>
        <source>Histopathology</source>
        <year>2004</year>
        <volume>45</volume>
        <issue>4</issue>
        <fpage>405</fpage>
        <lpage>411</lpage>
        <?supplied-pmid 15469480?>
        <pub-id pub-id-type="pmid">15469480</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Florenes</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Maelandsmo</surname>
            <given-names>GM</given-names>
          </name>
          <name>
            <surname>Faye</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Nesland</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Holm</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome</article-title>
        <source>J Pathol.</source>
        <year>2001</year>
        <volume>195</volume>
        <issue>5</issue>
        <fpage>530</fpage>
        <lpage>536</lpage>
        <?supplied-pmid 11745687?>
        <pub-id pub-id-type="pmid">11745687</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Sun</surname>
            <given-names>MY</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lv</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>XW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Critical role for non-GAP function of Gαs in RGS1-mediated promotion of melanoma progression through AKT and ERK phosphorylation</article-title>
        <source>Oncol Rep</source>
        <year>2018</year>
        <volume>39</volume>
        <issue>6</issue>
        <fpage>2673</fpage>
        <lpage>2680</lpage>
        <?supplied-pmid 29620236?>
        <pub-id pub-id-type="pmid">29620236</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Alonso</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Tracey</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Ortiz</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Perez-Gomez</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Palacios</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pollan</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis</article-title>
        <source>Cancer Res</source>
        <year>2007</year>
        <volume>67</volume>
        <issue>7</issue>
        <fpage>3450</fpage>
        <lpage>3460</lpage>
        <?supplied-pmid 17409456?>
        <pub-id pub-id-type="pmid">17409456</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Scala</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ottaiano</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ascierto</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Cavalli</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Simeone</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Giuliano</surname>
            <given-names>P</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma</article-title>
        <source>Clin Cancer Res</source>
        <year>2005</year>
        <volume>11</volume>
        <issue>5</issue>
        <fpage>1835</fpage>
        <lpage>1841</lpage>
        <?supplied-pmid 15756007?>
        <pub-id pub-id-type="pmid">15756007</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jonsson</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Bergman</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nodin</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Manjer</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ponten</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Uhlen</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmo Diet and Cancer Study</article-title>
        <source>J Transl Med.</source>
        <year>2011</year>
        <volume>9</volume>
        <fpage>114</fpage>
        <?supplied-pmid 21777469?>
        <pub-id pub-id-type="pmid">21777469</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Giatromanolaki</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Sivridis</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Kouskoukis</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Gatter</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Harris</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Koukourakis</surname>
            <given-names>MI</given-names>
          </name>
        </person-group>
        <article-title>Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin</article-title>
        <source>Melanoma Res</source>
        <year>2003</year>
        <volume>13</volume>
        <issue>5</issue>
        <fpage>493</fpage>
        <lpage>501</lpage>
        <?supplied-pmid 14512791?>
        <pub-id pub-id-type="pmid">14512791</pub-id>
      </element-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>HX</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>WJ</given-names>
          </name>
          <name>
            <surname>Niu</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>W</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Overexpression of kinesin family member 20A correlates with disease progression and poor prognosis in human nasopharyngeal cancer: a retrospective analysis of 105 patients</article-title>
        <source>PLoS ONE</source>
        <year>2017</year>
        <volume>12</volume>
        <issue>1</issue>
        <fpage>e169280</fpage>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Roh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Shin</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>AN</given-names>
          </name>
          <name>
            <surname>Yoon</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Suh</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>CJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>RGS1 expression is associated with poor prognosis in multiple myeloma</article-title>
        <source>J Clin Pathol</source>
        <year>2017</year>
        <volume>70</volume>
        <issue>3</issue>
        <fpage>202</fpage>
        <lpage>207</lpage>
        <?supplied-pmid 27445341?>
        <pub-id pub-id-type="pmid">27445341</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mattoscio</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Chiocca</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>SUMO pathway components as possible cancer biomarkers</article-title>
        <source>Future Oncol.</source>
        <year>2015</year>
        <volume>11</volume>
        <issue>11</issue>
        <fpage>1599</fpage>
        <lpage>1610</lpage>
        <?supplied-pmid 26043214?>
        <pub-id pub-id-type="pmid">26043214</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kessler</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Kahle</surname>
            <given-names>KT</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Meerbrey</surname>
            <given-names>KL</given-names>
          </name>
          <name>
            <surname>Schlabach</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Schmitt</surname>
            <given-names>EM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis</article-title>
        <source>Science</source>
        <year>2012</year>
        <volume>335</volume>
        <issue>6066</issue>
        <fpage>348</fpage>
        <lpage>353</lpage>
        <?supplied-pmid 22157079?>
        <pub-id pub-id-type="pmid">22157079</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Luo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Emanuele</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Creighton</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Schlabach</surname>
            <given-names>MR</given-names>
          </name>
          <name>
            <surname>Westbrook</surname>
            <given-names>TF</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene</article-title>
        <source>Cell</source>
        <year>2009</year>
        <volume>137</volume>
        <issue>5</issue>
        <fpage>835</fpage>
        <lpage>848</lpage>
        <?supplied-pmid 19490893?>
        <pub-id pub-id-type="pmid">19490893</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Malla</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Aylward</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Ward</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Knowledge translation for public health in low- and middle-income countries: a critical interpretive synthesis</article-title>
        <source>Glob Health Res Policy.</source>
        <year>2018</year>
        <volume>3</volume>
        <fpage>29</fpage>
        <?supplied-pmid 30377666?>
        <pub-id pub-id-type="pmid">30377666</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
